Bicara Therapeutics (BCAX) Q4 2025 earnings summary

Executive summary

• Achieved FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab for first-line metastatic or unresectable HPV-negative head and neck squamous cell carcinoma and advanced pivotal FORTIFY-HN01 study to Phase III, with substantial enrollment expected by end of 2026 and interim analysis in mid-2027.

• Selected 1500mg weekly dose as optimal and initiated studies for less frequent dosing regimens, with supporting efficacy and safety data from Phase 1b trials.

• Completed an oversubscribed public offering, raising $161.8 million to support clinical, commercial, and medical build-out for potential U.S. launch.

Financial highlights

• Total operating expenses for Q4 2025 were $32.99M, up from $19.88M in Q4 2024; full-year 2025 expenses reached $125.1M, compared to $63.6M in 2024.

• Net loss for Q4 2025 was $37.39M, compared to $20.96M in Q4 2024; full-year net loss was $137.95M, up from $67.99M in 2024.

• Cash, cash equivalents, and marketable securities stood at $414.8M as of December 31, 2025, bolstered by the Q1 2026 public offering.

• Raised $161.8M in Q1 2026 via an oversubscribed public offering, extending cash runway into the first half of 2029.

Outlook and guidance

• Interim analysis for pivotal study targeted for mid-2027, with substantial enrollment by end of 2026 and potential for accelerated approval based on response rate and durability endpoints.

• Key 2026 milestones include presenting long-term follow-up and exploratory cohort data, and making critical commercial hires to prepare for launch readiness.

• Cash position supports regulatory filing, commercial build, expanded development, and manufacturing for ficerafusp alfa.